1d
2
2
20
5
5
1e
5
1d
19a
c
27
1a
3f
21
c
1c
15
2
7
15
5
21
5
3
6
17
4
4
2
22
3
1a
4
8
1c
c
3
4e
16
9
c
19
1
49
2
6
d
1b
1d
18
89
31
1d 4 3 3 3 2 4 b 1f
2 29
1d
25
31
Casim A. Sarkar, PhD
4aAssociate Professor of Bioengineering
7
65
Department: Bioengineering
4
1
b
1d 4 3 3 3 2 4 b 1f
13
Education:
21 7 BS 21 (Chemical Engineering) c
36 University of Texas at Austin, 1997.
21 8 PhD 21 (Chemical Engineering) c
3e Massachusetts Institute of Technology, 2002.
c
3
3
21
21 7 BS 21 (Chemical Engineering) c
36 University of Texas at Austin, 1997.
21 8 PhD 21 (Chemical Engineering) c
3e Massachusetts Institute of Technology, 2002.
c
1f
Post-Graduate Training
24 57 Postdoctoral Fellow in Biochemistry, University of Zurich, 2002-2005.
c
3
3
8d
Permanent link24 57 Postdoctoral Fellow in Biochemistry, University of Zurich, 2002-2005.
c
2 29
21
1e
1d
24
76
e 29
27
Description of Research Expertise
56 Please see http://www.seas.upenn.edu/~caslab/ for further information.e 29
23
125 Peter Milovnik, Davide Ferrari, Casim A. Sarkar, and Andreas Plückthun: Selection and characterization of DARPins specific for the neurotensin receptor 1. Protein Engineering, Design & Selection 22(6): 357-66, Jun 2009.
18c Casim A. Sarkar, Igor Dodevski, Manca Kenig, Stefan Dudli, Anja Mohr, Emmanuel Hermans, and Andreas Plückthun: Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. Proceedings of the National Academy of Sciences of the United States of America 105(39): 14808-13, Sep 2008.
124 Santhosh Palani and Casim A. Sarkar: Positive receptor feedback during lineage commitment can generate ultrasensitivity to ligand and confer robustness to a bistable switch. Biophysical Journal 95(4): 1575-89, Aug 2008.
112 Susanne Kubetzko, Casim A. Sarkar, and Andreas Plückthun: Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Molecular Pharmacology 68(5): 1439-54, Nov 2005.
161 Casim A. Sarkar, Ky Lowenhaupt, Peggy J. Wang, Thomas Horan, and Douglas A. Lauffenburger: Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. Biotechnology Progress 19(3): 955-64, May-Jun 2003.
135 Margaret S. Ricci, Casim A. Sarkar, Eric M. Fallon, Douglas A. Lauffenburger, and David N. Brems: pH Dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor. Protein Science 12(5): 1030-8, May 2003.
127 Casim A. Sarkar and Douglas A. Lauffenburger: Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Molecular Pharmacology 63(1): 147-58, Jan 2003.
14f Casim A. Sarkar, Ky Lowenhaupt, Thomas Horan, Thomas C. Boone, Bruce Tidor, and Douglas A. Lauffenburger: Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nature Biotechnology 20(9): 908-13, Sep 2002.
2c
7
1d
1f
Selected Publications
115 Santhosh Palani and Casim A. Sarkar: Integrating extrinsic and intrinsic cues into a minimal model of lineage commitment for hematopoietic progenitors. PLoS Computational Biology 5(9): e1000518, Sep 2009.125 Peter Milovnik, Davide Ferrari, Casim A. Sarkar, and Andreas Plückthun: Selection and characterization of DARPins specific for the neurotensin receptor 1. Protein Engineering, Design & Selection 22(6): 357-66, Jun 2009.
18c Casim A. Sarkar, Igor Dodevski, Manca Kenig, Stefan Dudli, Anja Mohr, Emmanuel Hermans, and Andreas Plückthun: Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. Proceedings of the National Academy of Sciences of the United States of America 105(39): 14808-13, Sep 2008.
124 Santhosh Palani and Casim A. Sarkar: Positive receptor feedback during lineage commitment can generate ultrasensitivity to ligand and confer robustness to a bistable switch. Biophysical Journal 95(4): 1575-89, Aug 2008.
112 Susanne Kubetzko, Casim A. Sarkar, and Andreas Plückthun: Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Molecular Pharmacology 68(5): 1439-54, Nov 2005.
161 Casim A. Sarkar, Ky Lowenhaupt, Peggy J. Wang, Thomas Horan, and Douglas A. Lauffenburger: Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. Biotechnology Progress 19(3): 955-64, May-Jun 2003.
135 Margaret S. Ricci, Casim A. Sarkar, Eric M. Fallon, Douglas A. Lauffenburger, and David N. Brems: pH Dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor. Protein Science 12(5): 1030-8, May 2003.
127 Casim A. Sarkar and Douglas A. Lauffenburger: Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Molecular Pharmacology 63(1): 147-58, Jan 2003.
14f Casim A. Sarkar, Ky Lowenhaupt, Thomas Horan, Thomas C. Boone, Bruce Tidor, and Douglas A. Lauffenburger: Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nature Biotechnology 20(9): 908-13, Sep 2002.
2c
7
1e
18
18
6
9
b
26
b
22
10
cb
22
31
22
Contact us
4eInstitute for Diabetes, Obesity and Metabolism
3b
Smilow Center for Translational Research
37
3400 Civic Center Boulevard, 12th Floor
2a
Philadelphia, PA 19104
3a
Phone: 215-898-0198 | Fax 215-898-5408
31
12
Directions
120
18
37
e
54
10
© Trustees of the University of Pennsylvania
12